China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma

Stock News

08/04

CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).

The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed usingCARSGEN-B's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).

The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1151736677"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151736677\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151736677?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151736677","market":"sh","top_or_hot":-1,"title":"China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma","media":"Stock News","content":"<p><b>CARSGEN-B (02171)</b> has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).<br><br>The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed using<b>CARSGEN-B</b>'s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).<br><br>The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-08-04 08:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>CARSGEN-B (02171)</b> has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).<br><br>The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed using<b>CARSGEN-B</b>'s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).<br><br>The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科濟藥業-B","start_time":0,"source_url":"","article_id":"1151736677","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151736677","pubTimestamp":1785802452,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B","BK1587":"次新股","BK1161":"生物科技","BK1574":"生物医药B类股","BK1585":"昨日强势股","IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"中国批准CARSGEN-B针对BCMA的通用CAR-T治疗难治性骨髓瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"IND":1},"content_text":"CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed usingCARSGEN-B's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}